On September 4, 2023, leading pharmaceutical company Catalent (NYSE:CTLT) saw its price objective raised by Barclays analysts from $42.00 to $55.00, according to a note issued to investors by FlyOnTheWall. This increase in the price target suggests a potential upside of 10.07% from the stock’s current price.
Shares of Catalent opened at $49.97 on Friday. The stock has a 50-day moving average of $45.77 and a 200-day moving average of $50.66. Over the past 12 months, Catalent has seen a low of $31.45 and a high of $99.50. With a market capitalization of $9.01 billion, the company has a price-to-earnings ratio of 227.15, a price/earnings to growth ratio (PEG) of 5.96, and a beta value of 1.23. Additionally, it has a current ratio of 1.84, a quick ratio of 1.34, and a debt-to-equity ratio of 0.91.
Several institutional investors have recently made changes to their positions in CTLT (Catalent). KB Financial Partners LLC acquired shares in the first quarter worth approximately $30,000, while Compagnie Lombard Odier SCmA also purchased shares in the fourth quarter valued at around $34,000 . In addition to these acquisitions,FNY Investment Advisers LLC bought shares in the first quarter valued at about $34,000.Investors may also note that Optiver Holding B.V.and Harel Insurance Investments & Financial Services Ltd.each added new positions during this same time period—investing approximately$35,000and$48,000,respectively.
Catalent released its quarterly earnings results on August29th.A disappointing report for some analysts,it revealed($0.02)eps(lower than$0.11,equal to -$0.02),a return on equity of 7.13%,and a net margin of only 0.93%.The comapný’s reported revenue was $1.09 billion in the quarter,compared to the consensus estimate of $1.05billion.However,Catalent’s quarterly revenue also experienced a declineof 15.6% compared to the same period last year.On a more positive note,analysts expect that by the end of the current fiscal year,Catalent will have earned $0 .83 in EPS.
While these figures may contribute to a mixed outlook for investors, Barclays’ increased price objective indicates that analysts still believe in the company’s potential for growth.
-However, long-term shareholders must weigh these findings against their own investment goals; -considering whether now is an opportune time to buy–or sell—for themselves.Volatility,instability,and unforeseen circumstances may influence market movements further,and shareholders should stay informed regarding any such shifts or developments.
Overall preferences and strategies regarding investments remain subjective and depend on each individual investor’s appetite for risk and long-term financial objectives.Understanding one’s personal tolerance for potential losses–along with staying updated on Catalent’s financial performance and industry trends–will be crucial in making informed investment decisions going forward.
References:
“Barclays Raises Price Objective on Catalent (NYSE:CTLT).” FlyOnTheWall News, September4,2023
“Catalent Profile.” Yahoo Finance.Yahoo!,September4,2023
Catalent, Inc.
CTLT
Strong Buy
Updated on: 04/09/2023
An Array of Analyst Reports and Insider Sales Impact Catalent’s Stock Performance
An array of equities analysts have recently released reports on Catalent, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. Royal Bank of Canada (RBC) increased its price target on Catalent from $51.00 to $58.00 and assigned the company an “outperform” rating in a research note published last Wednesday. TheStreet, however, downgraded Catalent from a “c” rating to a “d+” rating in a research note dated June 12th. Meanwhile, Bank of America raised its price objective on Catalent from $39.00 to $46.00 in another research note published last Thursday.
In contradiction with RBC’s positive stance, Jefferies Financial Group had earlier revised their rating on Catalent from “buy” to “hold,” along with decreasing the price objective from $45.00 to $44.00, according to a research note dated June 14th. Adding further complexity to the situation is Deutsche Bank Aktiengesellschaft’s decision to raise their price objective on Catalent from $37.00 to $45.00 while maintaining a “hold” rating in a research note issued on August 15th.
Currently, the stock has garnered two sell ratings, eight hold ratings, and four buy ratings as per data sourced from Bloomberg.com. The consensus among experts suggests that investors should hold onto their shares at this moment since the stock’s overall performance remains uncertain at best.
In other developments surrounding Catalent, it was revealed that Executive Vice President (EVP) Steven L. Fasman sold 817 shares of the company’s stock in a transaction conducted on August 24th at an average price of $44.65 per share—an estimated total transaction value of $36,479.05. Following this sale, Fasman now holds 73,789 shares directly in the company, approximating a value of $3,294,678.85. This transaction was duly disclosed to the Securities and Exchange Commission (SEC) and can be accessed through their website.
Furthermore, it should be noted that Fasman was not the only executive to sell shares recently. CEO Alessandro Maselli also sold 2,071 shares on August 24th at an average price of $44.54 per share—a total value of $92,242.34. With this sale, Maselli’s direct ownership in Catalent now amounts to 88,004 shares equivalent to about $3,919,698.16 in value. The disclosure for Maselli’s transaction has been made available for public scrutiny.
Overall, within the past ninety days alone, insiders have already sold 5,442 shares of Catalent stock valued at approximately $247,577. It is worth noting that these insider sales amount to only 0.58% of the company’s total shares outstanding.
Catalent investors are advised to carefully evaluate these recent developments and exercise prudence when making investment decisions related to the company’s stock.
